79,967 results match your criteria Targeted Cancer Therapy

Advancements in folate receptor targeting for anti-cancer therapy: A small molecule-drug conjugate approach.

Bioorg Chem 2021 Apr 27;112:104946. Epub 2021 Apr 27.

Amity Institute of Biotechnology, Amity University, Sector125, Noida, Uttar Pradesh, India. Electronic address:

Targeted delivery combined with controlled release of drugs has a crucial role in future of personalized medicine. The majority of cancer drugs are intended to interfere with one or more cellular events. Anticancer agents can also be toxic to healthy cells, as healthy cells may also need to proliferate and avoid apoptosis. Read More

View Article and Full-Text PDF

Human serum albumin as multifunctional nanocarrier for cancer therapy.

J Pharm Sci 2021 May 11. Epub 2021 May 11.

Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi - 110062, India. Electronic address:

Human serum albumin or simply called albumin is a flexible protein employed as a carrier in the fabrication of albumin-based nanocarriers (ANCs) for the administration of cancer therapeutics. Albumin can contribute enhanced tumour specificity, reduced drug induced cytotoxicity and retain concentration of the therapeutically active agent such as drug, peptide, protein, and gene for a prolonged time duration. Nevertheless, apart from cancer management, ANCs are also employed in the diagnosis, imaging, and multimodal cancer therapy. Read More

View Article and Full-Text PDF

New approaches to targeting the androgen receptor pathway in prostate cancer.

Clin Adv Hematol Oncol 2021 Apr;19(4):228-240

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.

The androgen signaling axis has been the main therapeutic target in the management of advanced prostate cancer for several decades. Over the past years, significant advances have been made in terms of a better understanding the androgen receptor (AR) pathway and mechanisms of castration resistance, along with the development of more potent AR-targeted therapies. New drugs, such as abiraterone, enzalutamide, apalutamide, and darolutamide, have been approved for castration-resistant prostate cancer and also have demonstrated an overall survival benefit in the castration-sensitive state. Read More

View Article and Full-Text PDF

Tenascin-C immobilizes infiltrating T lymphocytes through CXCL12 promoting breast cancer progression.

EMBO Mol Med 2021 May 14:e13270. Epub 2021 May 14.

The Tumor Microenvironment Laboratory, INSERM UMR_S 1109, Faculté de Médecine, Hopital Civil, Institut d'Hématologie et d'Immunologie, Strasbourg, France.

Immune checkpoint therapy, where CD8 tumor infiltrating T lymphocytes (TIL) are reactivated, is a promising anti-cancer treatment approach, yet with low response rates. The extracellular matrix, in particular tenascin-C, may generate barriers for TIL. To investigate this possibility, we used a MMTV-NeuNT and syngeneic mammary gland grafting model derived thereof with engineered tenascin-C levels and observed accumulation of CD8 TIL in tenascin-C-rich stroma. Read More

View Article and Full-Text PDF

Progress in gene-therapy treatments for prostate cancer.

Biotechnol Appl Biochem 2021 May 14. Epub 2021 May 14.

Institute of Nano Electronic Engineering.

Prostate cancer is one of the predominant cancers affecting men and has been widely reported. In the past, various therapies and drugs have been proposed to treat prostate cancer. Among these treatments, gene therapy has been considered to be an optimal and widely applicable treatment. Read More

View Article and Full-Text PDF

Cellular mechanisms linking cancers to obesity.

Cell Stress 2021 Apr 12;5(5):55-72. Epub 2021 Apr 12.

Department of Biomedicine, University of Bergen, N-5020 Bergen, Norway.

Obesity is epidemiologically linked to 13 forms of cancer. The local and systemic obese environment is complex and likely affect tumors through multiple avenues. This includes modulation of cancer cell phenotypes and the composition of the tumor microenvironment. Read More

View Article and Full-Text PDF

Exploring the concepts and practices of advanced breast cancer treatment: a narrative review.

Ann Transl Med 2021 Apr;9(8):721

Department of Medical Oncology (Breast Cancer), Cancer Hospital of the University of Chinese Academy of Sciences/Zhejiang Cancer Hospital, Hangzhou, China.

Objective: To explore the concepts and practices of advanced breast cancer treatment.

Background: Metastatic breast cancer (MBC) has become a chronic disease, with a median overall survival (OS) of around 3 years and a 5-year survival rate of about 25%. OS are strongly associated with the best available care, which consists of not only application of guidelines, but also multidisciplinary specialized care, the most efficacious medicines, and so on. Read More

View Article and Full-Text PDF

Chinese expert consensus on technical recommendations for the standard operation of drug-eluting beads for transvascular embolization.

Ann Transl Med 2021 Apr;9(8):714

Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.

Liver cancer is among the 10 most common tumors globally. In China, liver cancer ranks 4 for prevalence and 3 for mortality among all malignant tumors. With respect to the treatment of primary liver cancer, there are a number of therapies currently available, including surgical resection, liver transplantation, ablation, transarterial chemoembolization (TACE), systemic chemotherapy, radiation therapy, targeted drug therapy and immunotherapy. Read More

View Article and Full-Text PDF

A prognostic predictive model constituted with gene mutations of , , , , and in colorectal cancer.

Ann Transl Med 2021 Apr;9(8):680

Department of Colorectal Oncology, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

Background: Colorectal cancer (CRC) is a malignant tumor that seriously threatens human health. A CRC predictive model can be used as an effective method to provide an appropriate treatment for CRC patients.

Methods: A total of 34 CRC patients were enrolled in this study. Read More

View Article and Full-Text PDF

Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world.

Ann Transl Med 2021 Apr;9(8):652

Liver Cancer Institute, Zhongshan Hospital, and Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Fudan University, Shanghai, China.

Background: This study aimed to evaluate safety and efficacy of programmed death-1 (PD-1) inhibitor sintilimab plus tyrosine kinase inhibitors (TKI) in a real-word cohort of patients with unresectable hepatocellular carcinoma (uHCC).

Methods: A total of 60 patients treated with sintilimab plus TKI between February 2019 and December 2019 were enrolled. Radiological response was recorded by computed tomography (CT) or magnetic resonance imaging (MRI) at baseline and every 6-12 weeks after treatment initiation. Read More

View Article and Full-Text PDF

Triple-negative breast cancer: A run-through of features, classification and current therapies.

Oncol Lett 2021 Jul 5;22(1):512. Epub 2021 May 5.

Department of Biotechnology, Institute of Bioinformatics and Applied Biotechnology, Bengaluru, Karnataka 560100, India.

Breast cancer is the most prevalent cancer in women worldwide. Triple-negative breast cancer (TNBC) is characterized by the lack of expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2. It is the most aggressive subtype of breast cancer and accounts for 12-20% of all breast cancer cases. Read More

View Article and Full-Text PDF

Long non-coding RNA USP30-AS1 aggravates the malignant progression of cervical cancer by sequestering microRNA-299-3p and thereby overexpressing PTP4A1.

Oncol Lett 2021 Jul 29;22(1):505. Epub 2021 Apr 29.

Department of Gynaecology, The First People's Hospital of Chongqing Liangjiang New Area, Chongqing 401120, P.R. China.

USP30 antisense RNA 1 (USP30-AS1) has been studied in bladder urothelial carcinoma. However, the detailed role of USP30-AS1 in cervical cancer remains to be elucidated. Therefore, the present study determined whether USP30-AS1 is implicated in cervical cancer malignancy, and investigated relevant molecular mechanisms. Read More

View Article and Full-Text PDF

Preclinical Advances in Theranostics for the Different Molecular Subtypes of Breast Cancer.

Front Pharmacol 2021 27;12:627693. Epub 2021 Apr 27.

PET Center, Department of Radiology and Biomedical Imaging, School of Medicine, Yale University, New Haven, CT, United States.

Breast cancer is the most common cancer in women worldwide. The heterogeneity of breast cancer and drug resistance to therapies make the diagnosis and treatment difficult. Molecular imaging methods with positron emission tomography (PET) and single-photon emission tomography (SPECT) provide useful tools to diagnose, predict, and monitor the response of therapy, contributing to precision medicine for breast cancer patients. Read More

View Article and Full-Text PDF

Did Everolimus Break the Rules?

Clin Cancer Res 2021 May 13. Epub 2021 May 13.

Moores Cancer Center, University of California, San Diego Health

A phase II study with everolimus (mTORC1 inhibitor) among advanced solid tumors patients with TSC1/TSC2 or MTOR alterations was recently published. Although efficacy was limited, the study provided the future groundwork to advance the targeted therapy approach. Read More

View Article and Full-Text PDF

[New data on the molecular biology of soft tissue sarcoma].

Sarah Watson

Bull Cancer 2021 May 10. Epub 2021 May 10.

Institut Curie, département d'oncologie médicale, Inserm U830, 26, rue d'Ulm, 75005 Paris, France. Electronic address:

Sarcoma consists in a group of rare malignant tumours of mesenchymal origin characterized by their vast clinical, pathological and biological heterogeneity. The pathological diagnosis of sarcoma relies classically of the differentiation features of tumour cells, with dozens of different tumour subtypes described in the last international classifications. Over the last decades, the advances in the development of new techniques of molecular biology have led to a major complexification of sarcoma classification, with the identification of multiple and specific molecular alterations that have led to significant changes for patients diagnostic, prognostic and therapeutic management. Read More

View Article and Full-Text PDF

Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy.

J Nanobiotechnology 2021 May 13;19(1):138. Epub 2021 May 13.

Department of Pharmacy, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, China.

Background: Solid tumor hypoxic conditions prevent the generation of reactive oxygen species (ROS) and the formation of DNA double-strand breaks (DSBs) induced by ionizing radiation, which ultimately contributes to radiotherapy (RT) resistance. Recently, there have been significant technical advances in nanomedicine to reduce hypoxia by facilitating in situ O production, which in turn serves as a "radiosensitizer" to increase the sensitivity of tumor cells to ionizing radiation. However, off-target damage to the tumor-surrounding healthy tissue by high-energy radiation is often unavoidable, and tumor cells that are further away from the focal point of ionizing radiation may avoid damage. Read More

View Article and Full-Text PDF

Biomimetic nanoreactor for targeted cancer starvation therapy and cascade amplificated chemotherapy.

Biomaterials 2021 May 7;274:120869. Epub 2021 May 7.

Jiangsu Engineering Laboratory of Smart Carbon-Rich Materials and Device, Jiangsu Province Hi-Tech Key Laboratory for Bio-Medical Research, School of Chemistry and Chemical Engineering, Southeast University, Nanjing, 211189, China.

Consuming glucose by glucose oxidase (GOx) has attracted great interest in cancer starvation therapy, but the therapeutic effect is severely limited by the tumor hypoxia environment. Herein, to overcome such limitation, cancer cell membranes disguised biomimetic nanoreactors were elaborately established for synergetic cancer starvation therapy and cascade amplificated hypoxia activated chemotherapy. Via a metallothionein-like self-assembly and infiltration approach, GOx and hypoxia activated prodrug banoxantrone (AQ4N) were efficiently loaded into metal-organic framework ZIF-8 nanocarriers to yield nanoreactor AQ4N/GOx@ZIF-8. Read More

View Article and Full-Text PDF

The Fanconi anemia ubiquitin E3 ligase complex as an anti-cancer target.

Mol Cell 2021 May 4. Epub 2021 May 4.

Genome Stability Unit, St. Vincent's Institute of Medical Research, Fitzroy, VIC, Australia; Department of Medicine (St. Vincent's), University of Melbourne, Fitzroy, VIC, Australia. Electronic address:

Agents that induce DNA damage can cure some cancers. However, the side effects of chemotherapy are severe because of the indiscriminate action of DNA-damaging agents on both healthy and cancerous cells. DNA repair pathway inhibition provides a less toxic and targeted alternative to chemotherapy. Read More

View Article and Full-Text PDF

Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates.

Oncology (Williston Park) 2021 May 13;35(5):249-254. Epub 2021 May 13.

Massachusetts General Hospital Cancer Center, Boston, MA.

Background: Triple-negative breast cancer (TNBC) is a biologically heterogeneous disease that is often associated with worse outcomes compared with other subtypes such as hormone receptor-positive tumors and HER2-positive tumors. While chemotherapy remains the mainstay of standard therapy for metastatic TNBC (mTNBC), several novel treatments have been developed over the past few years. In this review article, we review the major developments in the management of patients with mTNBC. Read More

View Article and Full-Text PDF

Current Biomarkers for Precision Medicine in Breast Cancer.

Adv Exp Med Biol 2021 ;1187:363-379

Center for Breast Cancer, National Cancer Center, Goyang-si, South Korea.

Breast cancer has become the prototypical solid tumor where targets have been identified within the tumor allowing for personalized approach for systemic therapy. Biomarkers are beginning to play an important role in preparing the way for precision treatment. Mandatory biomarkers for every newly diagnosed case of breast cancer are estrogen receptors and progesterone receptors in selecting patients for endocrine treatment and HER2 for identifying patients likely to benefit from antiHER2 therapy. Read More

View Article and Full-Text PDF
January 2021

Next-Generation Sequencing-Based Biomarkers in Breast Cancer.

Adv Exp Med Biol 2021 ;1187:323-335

Department of Surgery, Seoul National University College of Medicine, Seoul, South Korea.

For the realization of precision medicine in cancer treatment, discovery, and validation of clinically useful biomarker is the most important prerequisite. Biomarkers are needed and used for evaluation of cancer susceptibility, cancer screening (early detection), cancer subtyping, prediction of prognosis, decision of appropriate adjuvant therapy and duration of therapy, and for monitoring of recurrence. Biomarkers are also needed for decision of target therapy in metastatic cancer and monitoring of their response during follow-up. Read More

View Article and Full-Text PDF
January 2021

Theranostics for Breast Cancer Stem Cells.

Adv Exp Med Biol 2021 ;1187:267-281

Department of Radiology, Seoul National University & Seoul National University Hospital, Seoul, Republic of Korea.

Effectively targeting and treating breast cancer stem cells (BCSCs), which have been linked to tumor development and metastasis, and recurrence still remains a challenging issue in preclinic and clinic. Screening and identifying characteristic BCSC biomarkers is important for distinguishing BCSCs from differentiated tumor cells within the tumor mass. Molecular imaging and nanotechnology are evolving as new fields that have a potentially high research and clinical impact. Read More

View Article and Full-Text PDF
January 2021

Identification of the dominant angiogenic CXCL class chemokines associated with non-small cell lung cancer via bioinformatics tools.

Nese Unver

Med Oncol 2021 May 13;38(6):68. Epub 2021 May 13.

Department of Stem Cell Sciences, Graduate School of Health Sciences, Center for Stem Cell Research and Development, Hacettepe University, Sihhiye, 06100, Ankara, Turkey.

Chemokines play a critical role in lung cancer progression and metastasis. In non-small cell lung cancer, the determination of dominant angiogenic CXCL-type chemokines may increase the efficacy of targeted therapy and modulate the prognosis of lung cancer. Also, chemokine and chemokine receptors shape the immune response in the cross-talk between both cancer cells and immune cells in the tumor microenvironment. Read More

View Article and Full-Text PDF

Global changes to the chemotherapy service during the covid-19 pandemic.

J Oncol Pharm Pract 2021 May 13:10781552211015767. Epub 2021 May 13.

Department for Targeted Intervention, UCL/UCLH Surgical Outcomes Research Centre, Centre for Perioperative Medicine, University College London, London, UK.

Purpose: In response to the COVID-19 pandemic, changes to chemotherapy services were implemented as a means of managing imposed workload strains within health services and protecting patients from contracting COVID-19. Given the rapidly evolving nature of the pandemic many changes were rapidly adopted and were not substantiated by robust evidence. This study aimed to describe the changes adopted internationally to chemotherapy services, which may be used to guide future changes to treatment delivery. Read More

View Article and Full-Text PDF

Advanced uterine papillary serous cancer: Could there be a role for newer targeted therapeutic approaches or immune checkpoint inhibitors?

J Oncol Pharm Pract 2021 May 13:10781552211015769. Epub 2021 May 13.

Eisenhower Lucy Curci Cancer Center, Rancho Mirage, CA USA.

Background: Although now available in oncology clinics, comprehensive germline mutation testing is being performed only in a minority of patients with advanced uterine papillary serous cancer (UPSC). Some of these patients might harbor various targetable mutations, either heritable or acquired.Data sources: We conducted a retrospective cohort study involving all consecutive patients with UPSC treated at our institution from 2009-2019. Read More

View Article and Full-Text PDF

circBANP promotes colorectal cancer growth and metastasis via sponging let-7d-5p to modulate HMGA1/Wnt/β-catenin signaling.

Mol Ther Oncolytics 2021 Jun 23;21:119-133. Epub 2021 Mar 23.

Department of General Surgery, The Second Affiliated Hospital, Nanjing Medical University, Nanjing 210000, Jiangsu Province, P.R. China.

Colorectal cancer (CRC) is one of the most common and deadly cancers, and the incidence of CRC is on the rise. Due to the lack of early diagnosis method and high metastasis of the disease, the prognosis of CRC remains very poor. Exploring the underlying molecular mechanisms of CRC is very necessary for effective therapy. Read More

View Article and Full-Text PDF

Sequential Systemic Treatment in Advanced Hepatocellular Carcinoma Is Able to Prolong Median Survival to More than 3 Years in a Selected Real-World Cohort.

Visc Med 2021 Mar 7;37(2):87-93. Epub 2020 May 7.

I. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Introduction: The number of efficacious systemic agents for advanced hepatocellular carcinoma (HCC) has rapidly increased over the past 3 years. However, guidance for optimal sequential systemic treatment in patients with advanced disease and experience with outcome and safety profiles are lacking.

Objective: We aimed to assess efficacy and tolerability of sequential systemic therapy of advanced HCC. Read More

View Article and Full-Text PDF

Using Biosensors to Study Protein-Protein Interaction in the Hippo Pathway.

Front Cell Dev Biol 2021 26;9:660137. Epub 2021 Apr 26.

Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada.

The Hippo signaling network is dependent on protein-protein interactions (PPIs) as a mechanism of signal transduction to regulate organ size, cellular proliferation and differentiation, tumorigenesis, and other cellular processes. Current efforts aim to resolve the complex regulation of upstream Hippo components or focus on identifying targeted drugs for use in cancer therapy. Despite extensive characterization of the Hippo pathway interactome by affinity purification mass spectrometry (AP-MS) and other methodologies, previous research methods have not been sufficient to achieve these aims. Read More

View Article and Full-Text PDF

Brain Tumor Biobank Development for Precision Medicine: Role of the Neurosurgeon.

Front Oncol 2021 26;11:662260. Epub 2021 Apr 26.

Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, United States.

Neuro-oncology biobanks are critical for the implementation of a precision medicine program. In this perspective, we review our first year experience of a brain tumor biobank with integrated next generation sequencing. From our experience, we describe the critical role of the neurosurgeon in diagnosis, research, and precision medicine efforts. Read More

View Article and Full-Text PDF